Can a Two-Drug combo outsmart resistant lung cancer?
Disease control
Completed
This early-phase trial is testing whether adding an experimental drug called alisertib to the standard treatment osimertinib can help people with stage IV EGFR-mutant lung cancer. The study aims to find the safest dose of alisertib when given with osimertinib and to see how the c…
Phase: PHASE1 • Sponsor: Collin Blakely • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC